0 XP   0   0   0

Marksans Pharma Limited
Buy, Hold or Sell?

Should you buy, hold or sell Marksans Pharma Limited?

I guess you are interested in Marksans Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Marksans Pharma Limited

Let's start. I'm going to help you getting a better view of Marksans Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Marksans Pharma Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Marksans Pharma Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Marksans Pharma Limited. The closing price on 2023-02-07 was INR64.05 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Marksans Pharma Limited Daily Candlestick Chart
Marksans Pharma Limited Daily Candlestick Chart
Summary









1. Valuation of Marksans Pharma Limited




Current price per share

INR64.05

2. Growth of Marksans Pharma Limited




Is Marksans Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$145.4m$107.2m$38.2m26.3%

How much money is Marksans Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$22.3m$28.5m-$6.2m-27.8%
Net Profit Margin12.4%17.1%--

How much money comes from the company's main activities?

3. Financial Health of Marksans Pharma Limited




Comparing to competitors in the Drug Manufacturers - Major industry




  Industry Rankings (Drug Manufacturers - Major)  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Marksans Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Marksans Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of 12.4% means that ₹0.12 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Marksans Pharma Limited:

  • The MRQ is 12.4%. The company is making a huge profit. +2
  • The TTM is 12.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.4%TTM12.4%0.0%
TTM12.4%YOY17.1%-4.8%
TTM12.4%5Y10.2%+2.2%
5Y10.2%10Y9.6%+0.6%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ12.4%10.8%+1.6%
TTM12.4%10.8%+1.6%
YOY17.1%14.8%+2.3%
5Y10.2%12.2%-2.0%
10Y9.6%11.9%-2.3%
1.1.2. Return on Assets

Shows how efficient Marksans Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • 11.3% Return on Assets means that Marksans Pharma Limited generated ₹0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Marksans Pharma Limited:

  • The MRQ is 11.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 11.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ11.3%TTM11.3%0.0%
TTM11.3%YOY19.2%-8.0%
TTM11.3%5Y11.5%-0.3%
5Y11.5%10Y11.2%+0.3%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ11.3%1.8%+9.5%
TTM11.3%2.3%+9.0%
YOY19.2%3.0%+16.2%
5Y11.5%3.0%+8.5%
10Y11.2%2.7%+8.5%
1.1.3. Return on Equity

Shows how efficient Marksans Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • 15.4% Return on Equity means Marksans Pharma Limited generated ₹0.15 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Marksans Pharma Limited:

  • The MRQ is 15.4%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.4%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.4%TTM15.4%0.0%
TTM15.4%YOY26.6%-11.3%
TTM15.4%5Y16.3%-0.9%
5Y16.3%10Y20.8%-4.5%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ15.4%2.5%+12.9%
TTM15.4%3.9%+11.5%
YOY26.6%4.4%+22.2%
5Y16.3%4.2%+12.1%
10Y20.8%4.0%+16.8%

1.2. Operating Efficiency of Marksans Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Marksans Pharma Limited is operating .

  • Measures how much profit Marksans Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Marksans Pharma Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y7.8%-7.8%
5Y7.8%10Y9.6%-1.8%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.7%-29.7%
TTM-11.5%-11.5%
YOY-11.7%-11.7%
5Y7.8%12.0%-4.2%
10Y9.6%11.0%-1.4%
1.2.2. Operating Ratio

Measures how efficient Marksans Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.50 means that the operating costs are ₹0.50 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.502. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.502. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.502TTM0.5020.000
TTM0.502YOY0.450+0.052
TTM0.5025Y1.053-0.551
5Y1.05310Y1.246-0.193
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5020.475+0.027
TTM0.5020.425+0.077
YOY0.4500.731-0.281
5Y1.0530.943+0.110
10Y1.2460.983+0.263

1.3. Liquidity of Marksans Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A Current Ratio of 3.37 means the company has ₹3.37 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Marksans Pharma Limited:

  • The MRQ is 3.372. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.372. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.372TTM3.3720.000
TTM3.372YOY3.024+0.348
TTM3.3725Y2.657+0.715
5Y2.65710Y2.170+0.488
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3721.824+1.548
TTM3.3721.800+1.572
YOY3.0241.807+1.217
5Y2.6571.305+1.352
10Y2.1701.218+0.952
1.3.2. Quick Ratio

Measures if Marksans Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 2.48 means the company can pay off ₹2.48 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Marksans Pharma Limited:

  • The MRQ is 2.475. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.475. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.475TTM2.4750.000
TTM2.475YOY2.140+0.335
TTM2.4755Y1.595+0.881
5Y1.59510Y1.230+0.365
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4751.248+1.227
TTM2.4751.200+1.275
YOY2.1401.151+0.989
5Y1.5950.836+0.759
10Y1.2300.750+0.480

1.4. Solvency of Marksans Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Marksans Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Marksans Pharma Limited to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.27 means that Marksans Pharma Limited assets are financed with 26.7% credit (debt) and the remaining percentage (100% - 26.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.267. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.267. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.267TTM0.2670.000
TTM0.267YOY0.278-0.011
TTM0.2675Y0.304-0.037
5Y0.30410Y0.383-0.079
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2670.415-0.148
TTM0.2670.419-0.152
YOY0.2780.429-0.151
5Y0.3040.455-0.151
10Y0.3830.431-0.048
1.4.2. Debt to Equity Ratio

Measures if Marksans Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 36.4% means that company has ₹0.36 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Marksans Pharma Limited:

  • The MRQ is 0.364. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.364. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.364TTM0.3640.000
TTM0.364YOY0.386-0.021
TTM0.3645Y0.439-0.075
5Y0.43910Y0.776-0.337
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3640.675-0.311
TTM0.3640.698-0.334
YOY0.3860.738-0.352
5Y0.4390.840-0.401
10Y0.7760.814-0.038

2. Market Valuation of Marksans Pharma Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Marksans Pharma Limited generates.

  • Above 15 is considered overpriced but always compare Marksans Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A PE ratio of 10.10 means the investor is paying ₹10.10 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Marksans Pharma Limited:

  • The EOD is 14.204. Very good. +2
  • The MRQ is 10.102. Very good. +2
  • The TTM is 10.102. Very good. +2
Trends
Current periodCompared to+/- 
EOD14.204MRQ10.102+4.103
MRQ10.102TTM10.1020.000
TTM10.102YOY8.665+1.436
TTM10.1025Y15.252-5.151
5Y15.25210Y39.489-24.237
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD14.20473.229-59.025
MRQ10.10266.328-56.226
TTM10.10260.797-50.695
YOY8.66533.289-24.624
5Y15.25260.412-45.160
10Y39.48964.422-24.933
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Marksans Pharma Limited.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Marksans Pharma Limited:

  • The MRQ is 12.913. Seems overpriced? -1
  • The TTM is 12.913. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ12.913TTM12.9130.000
TTM12.913YOY4.298+8.615
TTM12.9135Y7.334+5.579
5Y7.33410Y253.125-245.790
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ12.913-0.235+13.148
TTM12.9130.137+12.776
YOY4.2980.124+4.174
5Y7.3340.232+7.102
10Y253.1250.222+252.903

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Marksans Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 1.55 means the investor is paying ₹1.55 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Marksans Pharma Limited:

  • The EOD is 2.181. Good. +1
  • The MRQ is 1.551. Good. +1
  • The TTM is 1.551. Good. +1
Trends
Current periodCompared to+/- 
EOD2.181MRQ1.551+0.630
MRQ1.551TTM1.5510.000
TTM1.551YOY2.306-0.756
TTM1.5515Y1.876-0.325
5Y1.87610Y3.464-1.588
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD2.1811.495+0.686
MRQ1.5511.439+0.112
TTM1.5511.890-0.339
YOY2.3062.460-0.154
5Y1.8761.972-0.096
10Y3.4642.221+1.243
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Marksans Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--7.7157.7150%6.120+26%3.757+105%3.264+136%
Book Value Growth--1.3561.3560%1.394-3%1.232+10%1.3610%
Book Value Per Share--29.37329.3730%21.658+36%18.265+61%13.989+110%
Book Value Per Share Growth--1.3561.3560%1.394-3%1.232+10%1.3610%
Current Ratio--3.3723.3720%3.024+12%2.657+27%2.170+55%
Debt To Asset Ratio--0.2670.2670%0.278-4%0.304-12%0.383-30%
Debt To Equity Ratio--0.3640.3640%0.386-6%0.439-17%0.776-53%
Dividend Per Share--0.2590.2590%0.100+159%0.250+4%0.269-4%
Dividend Per Share Growth--2.5862.5860%0.139+1764%2.267+14%1.981+30%
Eps--4.5094.5090%5.764-22%3.161+43%2.485+81%
Eps Growth--0.7820.7820%2.016-61%2.075-62%1.591-51%
Free Cash Flow Per Share--1.2931.2930%3.233-60%1.764-27%1.136+14%
Free Cash Flow Per Share Growth--0.4000.4000%0.880-55%3.139-87%2.329-83%
Free Cash Flow To Equity Per Share--3.2363.2360%2.859+13%1.552+108%0.834+288%
Free Cash Flow To Equity Per Share Growth--1.1321.1320%1.945-42%3.339-66%2.733-59%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--17.953--------
Intrinsic Value_10Y_min--15.224--------
Intrinsic Value_1Y_max--1.405--------
Intrinsic Value_1Y_min--1.366--------
Intrinsic Value_3Y_max--4.522--------
Intrinsic Value_3Y_min--4.266--------
Intrinsic Value_5Y_max--8.001--------
Intrinsic Value_5Y_min--7.322--------
Net Profit Margin--0.1240.1240%0.171-28%0.102+21%0.096+29%
Operating Margin----0%-0%0.078-100%0.096-100%
Operating Ratio--0.5020.5020%0.450+12%1.053-52%1.246-60%
Pb Ratio2.181+29%1.5511.5510%2.306-33%1.876-17%3.464-55%
Pe Ratio14.204+29%10.10210.1020%8.665+17%15.252-34%39.489-74%
Peg Ratio--12.91312.9130%4.298+200%7.334+76%253.125-95%
Price Per Share64.050+29%45.55045.5500%49.950-9%33.180+37%38.317+19%
Price To Total Gains Ratio8.033+29%5.7135.7130%8.031-29%12.843-56%81.478-93%
Profit Growth--0.7820.7820%2.016-61%2.075-62%1.591-51%
Quick Ratio--2.4752.4750%2.140+16%1.595+55%1.230+101%
Return On Assets--0.1130.1130%0.192-41%0.115-2%0.112+1%
Return On Equity--0.1540.1540%0.266-42%0.163-6%0.208-26%
Revenue Growth--1.0831.0830%1.213-11%1.143-5%1.120-3%
Total Gains Per Share--7.9737.9730%6.220+28%4.006+99%3.532+126%
Total Gains Per Share Growth--1.2821.2820%2.069-38%3.969-68%2.717-53%
Usd Book Value--145474670.000145474670.0000%107265889.676+36%90462652.443+61%69280931.889+110%
Usd Book Value Change Per Share--0.0930.0930%0.074+26%0.045+105%0.039+136%
Usd Book Value Per Share--0.3550.3550%0.262+36%0.221+61%0.169+110%
Usd Dividend Per Share--0.0030.0030%0.001+159%0.003+4%0.003-4%
Usd Eps--0.0550.0550%0.070-22%0.038+43%0.030+81%
Usd Free Cash Flow----0%-0%-0%-0%
Usd Free Cash Flow Per Share--0.0160.0160%0.039-60%0.021-27%0.014+14%
Usd Free Cash Flow To Equity Per Share--0.0390.0390%0.035+13%0.019+108%0.010+288%
Usd Price Per Share0.775+29%0.5510.5510%0.604-9%0.401+37%0.464+19%
Usd Profit--22332849.00022332849.0000%28548727.900-22%15655669.555+43%12309502.549+81%
Usd Revenue--180391519.000180391519.0000%166518004.213+8%143118583.725+26%121015636.940+49%
Usd Total Gains Per Share--0.0960.0960%0.075+28%0.048+99%0.043+126%
 EOD+2 -3MRQTTM+0 -0YOY+19 -215Y+27 -1410Y+27 -14

3.2. Fundamental Score

Let's check the fundamental score of Marksans Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.204
Price to Book Ratio (EOD)Between0-12.181
Net Profit Margin (MRQ)Greater than00.124
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.475
Current Ratio (MRQ)Greater than13.372
Debt to Asset Ratio (MRQ)Less than10.267
Debt to Equity Ratio (MRQ)Less than10.364
Return on Equity (MRQ)Greater than0.150.154
Return on Assets (MRQ)Greater than0.050.113
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Marksans Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose62.500
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets16,401,000
Total Liabilities4,378,300
Total Stockholder Equity12,022,700
 As reported
Total Liabilities 4,378,300
Total Stockholder Equity+ 12,022,700
Total Assets = 16,401,000

Assets

Total Assets16,401,000
Total Current Assets12,012,000
Long-term Assets12,012,000
Total Current Assets
Cash And Cash Equivalents 1,566,860
Short-term Investments 1,402,870
Net Receivables 3,947,780
Inventory 4,244,420
Other Current Assets 322,320
Total Current Assets  (as reported)12,012,000
Total Current Assets  (calculated)11,484,250
+/- 527,750
Long-term Assets
Property Plant Equipment 3,422,870
Goodwill 300,250
Intangible Assets 585,690
Long-term Assets  (as reported)0
Long-term Assets  (calculated)4,308,810
+/- 4,308,810

Liabilities & Shareholders' Equity

Total Current Liabilities3,562,180
Long-term Liabilities-
Total Stockholder Equity12,022,700
Total Current Liabilities
Short-term Debt 412,920
Total Current Liabilities  (as reported)3,562,180
Total Current Liabilities  (calculated)412,920
+/- 3,149,260
Long-term Liabilities
Long term Debt Total 414,340
Capital Lease Obligations Min Short Term Debt-412,920
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)1,420
+/- 1,420
Total Stockholder Equity
Common Stock409,310
Retained Earnings 9,246,580
Capital Surplus 1,731,870
Other Stockholders Equity 634,940
Total Stockholder Equity (as reported)12,022,700
Total Stockholder Equity (calculated)12,022,700
+/-0
Other
Cash And Equivalents497,200
Cash and Short Term Investments 3,466,930
Common Stock Shares Outstanding 409,314
Liabilities and Stockholders Equity 16,401,000



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
4,900,953
6,755,546
7,199,981
7,518,058
7,321,852
8,037,084
8,968,401
12,282,511
16,401,000
16,401,00012,282,5118,968,4018,037,0847,321,8527,518,0587,199,9816,755,5464,900,953
   > Total Current Assets 
3,429,451
5,088,315
4,402,419
4,838,826
4,505,367
5,314,419
5,901,874
9,022,513
12,012,000
12,012,0009,022,5135,901,8745,314,4194,505,3674,838,8264,402,4195,088,3153,429,451
       Cash And Cash Equivalents 
469,470
1,852,652
353,013
250,494
397,166
328,550
937,271
515,988
1,566,860
1,566,860515,988937,271328,550397,166250,494353,0131,852,652469,470
       Short-term Investments 
0
0
0
0
0
0
0
1,577,816
1,402,870
1,402,8701,577,8160000000
       Net Receivables 
1,696,072
1,834,544
2,172,930
2,475,811
1,769,056
1,765,969
2,433,517
2,713,813
3,947,780
3,947,7802,713,8132,433,5171,765,9691,769,0562,475,8112,172,9301,834,5441,696,072
       Inventory 
1,025,887
1,301,068
1,677,917
1,900,870
2,181,241
2,932,461
2,418,439
4,043,197
4,244,420
4,244,4204,043,1972,418,4392,932,4612,181,2411,900,8701,677,9171,301,0681,025,887
       Other Current Assets 
238,021
100,051
3,772
2,024
100,980
217,212
110,601
171,700
322,320
322,320171,700110,601217,212100,9802,0243,772100,051238,021
   > Long-term Assets 
0
0
0
2,684,683
2,801,941
2,722,664
3,066,528
0
0
003,066,5282,722,6642,801,9412,684,683000
       Property Plant Equipment 
724,825
1,023,705
1,641,388
1,648,624
1,863,685
1,980,821
2,200,764
2,540,209
3,422,870
3,422,8702,540,2092,200,7641,980,8211,863,6851,648,6241,641,3881,023,705724,825
       Goodwill 
311,178
282,927
779,015
696,829
617,487
314,499
243,758
195,862
300,250
300,250195,862243,758314,499617,487696,829779,015282,927311,178
       Intangible Assets 
420,493
352,344
276,142
327,898
312,603
401,943
826,398
474,357
585,690
585,690474,357826,398401,943312,603327,898276,142352,344420,493
> Total Liabilities 
3,412,773
2,876,906
2,751,115
3,183,734
2,613,206
2,612,260
2,608,259
3,417,561
4,378,300
4,378,3003,417,5612,608,2592,612,2602,613,2063,183,7342,751,1152,876,9063,412,773
   > Total Current Liabilities 
3,191,194
2,862,355
2,511,203
2,960,583
2,346,796
2,326,242
2,196,858
2,983,994
3,562,180
3,562,1802,983,9942,196,8582,326,2422,346,7962,960,5832,511,2032,862,3553,191,194
       Short-term Debt 
2,219,326
1,220,113
878,929
1,097,103
1,174,132
999,087
188,425
187,400
412,920
412,920187,400188,425999,0871,174,1321,097,103878,9291,220,1132,219,326
       Short Long Term Debt 
2,219,326
1,220,113
884,812
1,097,103
1,179,621
1,002,165
188,884
0
0
00188,8841,002,1651,179,6211,097,103884,8121,220,1132,219,326
       Accounts payable 
831,818
1,070,195
1,189,802
1,617,841
674,806
1,060,692
1,045,010
0
0
001,045,0101,060,692674,8061,617,8411,189,8021,070,195831,818
       Other Current Liabilities 
301,293
523,437
464,946
5,993
5,828
132,602
885,076
0
0
00885,076132,6025,8285,993464,946523,437301,293
   > Long-term Liabilities 
0
0
0
0
156,371
183,850
280,300
0
0
00280,300183,850156,3710000
       Long term Debt Total 
0
0
125,000
110,000
100,000
100,000
50,000
143,257
414,340
414,340143,25750,000100,000100,000110,000125,00000
       Capital Lease Obligations 
0
0
0
0
0
0
107,615
0
0
00107,615000000
> Total Stockholder Equity
1,286,824
3,672,639
4,448,865
4,334,325
4,708,646
5,424,823
6,360,143
8,864,950
12,022,700
12,022,7008,864,9506,360,1435,424,8234,708,6464,334,3254,448,8653,672,6391,286,824
   Common Stock
385,307
409,314
409,314
409,314
409,314
409,314
409,314
409,314
409,310
409,310409,314409,314409,314409,314409,314409,314409,314385,307
   Retained Earnings 
518,755
1,611,772
2,258,024
2,175,794
2,481,786
3,202,272
5,950,829
6,571,749
9,246,580
9,246,5806,571,7495,950,8293,202,2722,481,7862,175,7942,258,0241,611,772518,755
   Accumulated Other Comprehensive Income 000000000
   Capital Surplus 
0
0
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,751,317
1,731,870
1,731,8701,751,3171,751,3171,751,3171,751,3171,751,3171,751,31700
   Treasury Stock000000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue14,908,390
Cost of Revenue-7,480,160
Gross Profit7,428,2307,428,230
 
Operating Income (+$)
Gross Profit7,428,230
Operating Expense--
Operating Income2,141,0407,428,230
 
Operating Expense (+$)
Research Development-
Selling General Administrative4,541,470
Selling And Marketing Expenses-
Operating Expense-4,541,470
 
Net Interest Income (+$)
Interest Income264,350
Interest Expense--
Net Interest Income-264,350
 
Pretax Income (+$)
Operating Income2,141,040
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)2,475,1102,141,040
EBIT - interestExpense = 0
1,845,690
1,845,690
Interest Expense-
Earnings Before Interest and Taxes (ebit)-2,475,110
Earnings Before Interest and Taxes (ebitda)-
 
After tax Income (+$)
Income Before Tax2,475,110
Tax Provision-606,970
Net Income From Continuing Ops-1,868,140
Net Income1,845,690
Net Income Applicable To Common Shares1,845,690
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
VAVA.XETRA
3 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of VAVA.XETRA.

VAVA.XETRA Daily Candlestick Chart
O39.SG
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of O39.SG.

O39.SG Daily Candlestick Chart
M44U.SG
12 minutes ago

I found you a Golden Cross on the daily chart of M44U.SG.

M44U.SG Daily Candlestick Chart
F9D.SG
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of F9D.SG.

F9D.SG Daily Candlestick Chart
A7RU.SG
17 minutes ago

I found you a Golden Cross on the daily chart of A7RU.SG.

A7RU.SG Daily Candlestick Chart
CHJ.SG
18 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHJ.SG.

CHJ.SG Daily Candlestick Chart
PSE.VN
23 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PSE.VN.

PSE.VN Daily Candlestick Chart
QTXB.PINK
41 minutes ago

I found you a MACD Bearish Reversal Divergence on the daily chart of QTXB.PINK.

QTXB.PINK Daily Candlestick Chart
33637L.KO
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 33637L.KO.

33637L.KO Daily Candlestick Chart
LOOMIS.ST
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LOOMIS.ST.

LOOMIS.ST Daily Candlestick Chart
KFAST-B.ST
1 hour ago

I found you a Golden Cross on the daily chart of KFAST-B.ST.

KFAST-B.ST Daily Candlestick Chart
COALA.ST
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of COALA.ST.

COALA.ST Daily Candlestick Chart
CFISH.ST
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CFISH.ST.

CFISH.ST Daily Candlestick Chart
UIFS.LSE
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of UIFS.LSE.

UIFS.LSE Daily Candlestick Chart
RNF.F
1 hour ago

I found you a RSI Bullish Hidden Divergence on the daily chart of RNF.F.

RNF.F Daily Candlestick Chart
IXX.F
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of IXX.F.

IXX.F Daily Candlestick Chart
4AP.F
1 hour ago

I found you a MACD Bearish Hidden Divergence on the daily chart of 4AP.F.

4AP.F Daily Candlestick Chart
5IC.SG
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 5IC.SG.

5IC.SG Daily Candlestick Chart
INFOMEDIA.BSE
4 hours ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of INFOMEDIA.BSE.

INFOMEDIA.BSE Daily Candlestick Chart
PNAX.TA
4 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PNAX.TA.

PNAX.TA Daily Candlestick Chart
SHI.VN
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SHI.VN.

SHI.VN Daily Candlestick Chart
HLC.VN
4 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of HLC.VN.

HLC.VN Daily Candlestick Chart
VPI.VN
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VPI.VN.

VPI.VN Daily Candlestick Chart
CIA.VN
4 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of CIA.VN.

CIA.VN Daily Candlestick Chart
GKM.VN
4 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GKM.VN.

GKM.VN Daily Candlestick Chart